Related references
Note: Only part of the references are listed.RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases
Jean-Nicolas Vauthey et al.
ANNALS OF SURGERY (2013)
Somatic Mutations of K-Ras and BRAF in Thai Colorectal Cancer and their Prognostic Value
Welawee Chaiyapan et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2013)
High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer
Joana G. Guedes et al.
BMC CANCER (2013)
Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens Clinical outcome and biomarkers of efficacy
Filippo Pietrantonio et al.
CANCER BIOLOGY & THERAPY (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
High-Resolution Melting Analysis as a Sensitive Prescreening Diagnostic Tool to Detect KRAS, BRAF, PIK3CA, and AKT1 Mutations in Formalin-Fixed, Paraffin-Embedded Tissues
Jasmin Teresa Ney et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing
Emma Borras et al.
BMC CANCER (2011)
Frequency of KRAS, BRAF, and NRAS Mutations in Colorectal Cancer
Cecily P. Vaughn et al.
GENES CHROMOSOMES & CANCER (2011)
Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia
Fortunato Ciardiello et al.
TARGETED ONCOLOGY (2011)
NRAS Mutations Are Rare in Colorectal Cancer
Natsumi Irahara et al.
DIAGNOSTIC MOLECULAR PATHOLOGY (2010)
Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer
Marc Peeters et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Randomized, Phase III Trial of Panitumumab With Infusional Fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX4) Versus FOLFOX4 Alone As First-Line Treatment in Patients With Previously Untreated Metastatic Colorectal Cancer: The PRIME Study
Jean-Yves Douillard et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
Two Multiplex Assays That Simultaneously Identify 22 Possible Mutation Sites in the KRAS, BRAF, NRAS and PIK3CA Genes
Irene Lurkin et al.
PLOS ONE (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR
Volker Heinemann et al.
CANCER TREATMENT REVIEWS (2009)
High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer
Lisa Simi et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies
Hongdo Do et al.
BMC CANCER (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples:: KRAS codon 12 and 13 mutations in non-small cell lung cancer
Michael Krypuy et al.
BMC CANCER (2006)
A single, multiplex analysis for all relevant activating NRAS gene mutations using heteroduplex generators
C Belli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
A modified mutagenic PCR-RFLP method for K-ras codon 12 and 13 mutations detection in NSCLC patients
A Hatzaki et al.
MOLECULAR AND CELLULAR PROBES (2001)
Share Paper
